Amarin Corp Plc (AMRN)

[sts66]

I thought the same initially when I read that - but don't forget it includes the word "global" - much easier to hit $1B in sales when you're able to sell in the EU. Assuming V follows a similar track, and it should do so easily given that we have zero competition, whereas the diabetes market is filled with them, our "launch" is 2020, and > $1B sales should be hit in 2021 (US only). Medicare Part D plans moving V up a tier to preferred brand will provide a major boost in 2021 - I'm hopeful it might happen in H2/2020 but not counting on it - since I've been on Medicare (2010) none of my plans have changed coverage levels of a drug I take during a plan year, they only updated formularies for the next plan year prior to the start of open season.